Torasemide extended release - Sarfez Pharmaceuticals

Drug Profile

Torasemide extended release - Sarfez Pharmaceuticals

Alternative Names: Torsemide extended release - Sarfez Pharmaceuticals

Latest Information Update: 19 Nov 2013

Price : $50

At a glance

  • Originator Sarfez Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Small molecules; Sulfonamides
  • Mechanism of Action Loop diuretics; Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Oedema

Most Recent Events

  • 12 Nov 2013 Phase-I clinical trials in Oedema in USA (PO) prior to November 2013
  • 12 Nov 2013 Sarfez Pharmaceuticals completes a phase I trial in healthy volunteers in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top